Stock Events

Stock Events

Exicure 

$1.4200
58
-$0.01-0.7% 08:00 Today

Statistics

Day High
1.42
Day Low
1.42
52W High
9.48
52W Low
1.18
Volume
916
Avg. Volume
-
Mkt Cap
9.36M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12NovExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q3 2025
Next
Next
-0.39
-0.06
0.28
0.61
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-4.95MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XCUR. It's not an investment recommendation.
Apple
8
AAPL
Tesla
8
TSLA
NVIDIA
8
NVDA
Bitcoin
8
BTC.CRYPTO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.6B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, directly competing with Exicure's spherical nucleic acid (SNA) technology.
Ionis Pharmaceuticals
IONS
Mkt Cap9.51B
Ionis Pharmaceuticals specializes in antisense technology, which is a form of RNA-targeted therapy competing with Exicure's approach.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap12.24B
Arrowhead Pharmaceuticals develops drugs based on RNA interference, a similar field to Exicure's, making them direct competitors.
Moderna
MRNA
Mkt Cap25.28B
Moderna is known for mRNA technology, which, while different, competes in the broader space of nucleic acid therapies where Exicure operates.
BioNTech
BNTX
Mkt Cap23.38B
BioNTech SE, although famous for its mRNA COVID-19 vaccine, works on nucleic acid technologies that compete with Exicure's SNA platform.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is focused on gene editing, a different but competing approach to treating diseases at the genetic level compared to Exicure.
Editas Medicine
EDIT
Mkt Cap433.1M
Editas Medicine operates in the gene editing space with CRISPR technology, offering a competing approach to Exicure's genetic intervention strategies.
Intellia Therapeutics
NTLA
Mkt Cap1.67B
Intellia Therapeutics is another key player in CRISPR-based gene editing, competing in the broader market of genetic therapies against Exicure.
Sarepta Therapeutics
SRPT
Mkt Cap1.91B
Sarepta Therapeutics focuses on RNA-targeted treatments, particularly for rare diseases, competing with Exicure's RNA-based therapeutic approaches.

About

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
Show more...
CEO
Jungsoo Kim
Employees
8
Country
United States
ISIN
US30205M3097
WKN
000A40L5C

Listings

STU
DE
2H0.STU
MU
DE
2H0.MU
F
DE
2H0.F
XNAS
US
XCUR

0 Comments

Share your thoughts

FAQ

What is Exicure stock price today?▼
The current price of XCUR is $1.42 USD — it has decreased by -0.7% in the past 24 hours. Watch Exicure stock price performance more closely on the chart.
What is Exicure stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Exicure stocks are traded under the ticker XCUR.
Is Exicure stock price growing?▼
XCUR stock has risen by +10% compared to the previous week, the month change is a -14.88% fall, over the last year Exicure has showed a -77.66% decrease.
What is Exicure market cap?▼
Today Exicure has the market capitalization of 9.36M
When is the next Exicure earnings date?▼
Exicure is going to release the next earnings report on November 12, 2026.
What is Exicure revenue for the last year?▼
Exicure revenue for the last year amounts to 0 USD.
What is Exicure net income for the last year?▼
XCUR net income for the last year is -4.95M USD.
How many employees does Exicure have?▼
As of August 19, 2026, the company has 8 employees.
In which sector is Exicure located?▼
Exicure operates in the Health & Wellness sector.
When did Exicure complete a stock split?▼
The last stock split for Exicure was on August 28, 2024 with a ratio of 1:5.
Where is Exicure headquartered?▼
Exicure is headquartered in CHICAGO, United States.